Seattle Genetics Inc. and Takeda Pharmaceutical Co. Ltd. reported top-line results on Oct. 1 for Adcetris (brentuximab vedotin) from the Phase III ECHELON-2 clinical trial in previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL), showing an improvement in survival that may lead to a sixth indication for the product.
Seattle Genetics CEO Clay Siegall couldn't provide specifics about the timing of a supplemental biologics license application (sBLA) submission to the US FDA, but told Scrip the company is "working at top speed to get this done
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?